VinBrain makes a strong impact at Top Hepatology Conference in Asia-Pacific with DrAid™ CT Liver Cancer D&T

On March 29th, following a rigorous selection process spanning over six months, VinBrain and its cutting-edge AI solution for early diagnosis and treatment support of liver cancer, DrAid™ CT Liver Cancer D&T, left a notable impression at the annual Asian Pacific Association for the Study of the Liver conference (APASL 2024) held in Kyoto, Japan. The company's CEO, Mr. Steven Truong, delivered a specialized presentation titled "Automated Abdomen CT Diagnosis Pipeline for Hepatocellular Carcinoma", a pioneering platform that addresses liver cancer challenges through artificial intelligence (AI). There are few global techniques that can segment liver lesions and tumors based on multi-phase CT images like VinBrain's DrAid™ CT Liver Cancer D&T due to the complexity of these phases. 

DrAid™ CT Liver Cancer D&T has attracted the attention of medical experts at the event

With over 30 years of history, APASL has witnessed the development of numerous cutting-edge technologies and diagnostic methods, such as advancements in medical imaging using Doppler ultrasound, CT scans, and MRI for liver disease assessment. As AI increasingly infiltrates the medical field, VinBrain's groundbreaking AI application, DrAid™ CT Liver Cancer D&T, attracted significant attention from healthcare professionals at the event. Its ability to automatically detect liver tumors as small as 5mm on multi-phase CT images garnered interest. This innovation not only aids in tumor detection but also supports specialist physicians in treatment by providing essential information about tumor size, location, and type. 

DrAid™ CT Liver Cancer D&T is trained on a large input dataset

Trained on a large, high-quality, and diverse input medical dataset from multiple countries and meticulously labeled and validated by experienced diagnostic radiologists from Vietnam and American hospitals, DrAid™ CT Liver Cancer D&T exhibits very high specificity and sensitivity, with a Dice coefficient for liver segmentation of 96.55% and a Dice coefficient for tumor segmentation of 74.47%, compared to an interobserver agreement rate among physicians of around 60%. 

The event attracted leading experts from around the globe, creating a forum to discuss critical topics in liver health such as hepatitis, cirrhosis, liver cancer, along with diagnostics and treatments. 

The APASL event attracts thousands of medical experts from around the world every year

After the conference, VinBrain's CEO Truong Quoc Hung delved into in-depth discussions with esteemed medical professionals and pathologists from Japan, the United States, and other nations. These interactions set the stage for potential international collaborations, investments in products, and early market commercialization in Asia-Pacific, where the demand is high, and the solutions are directly applicable. 

CEO Steven Truong engages in discussions with top experts from around the world

VinBrain, through the event, has levered this opportunity to reinforce its role in healthcare technology and its dedication to enhancing health outcomes worldwide.